Eplerenone

nuclear receptor subfamily 3 group C member 2 ; Homo sapiens







129 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
51 26572910 Predicting the relative binding affinity of mineralocorticoid receptor antagonists by density functional methods. 2015 Dec 1
52 27057293 Mineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart Failure. 2015 Oct-Dec 1
53 28834677 Efficacy of mineralocorticoid receptor antagonism in the acute myocardial infarction phase: eplerenone versus spironolactone. 2015 Sep 2
54 24297687 Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). 2014 Jan 1
55 24486397 Eplerenone mimics features of the alternative activation in macrophages obtained from patients with heart failure and healthy volunteers. 2014 Mar 5 1
56 24493871 Aldosterone synthase inhibitors in cardiovascular and renal diseases. 2014 Feb 1
57 24713303 Mineralocorticoid receptor function in bone metabolism and its role in glucocorticoid-induced osteopenia. 2014 May 9 1
58 25016400 Comparison of agents that affect aldosterone action. 2014 May 1
59 25016401 Aldosterone blockade in chronic kidney disease. 2014 May 1
60 23006216 Effect of low dose mineralocorticoid receptor antagonist eplerenone on glucose and lipid metabolism in healthy adult males. 2013 Mar 1
61 23171954 Mineralocorticoid receptor antagonists: their use and differentiation in Japan. 2013 Mar 1
62 23333184 Mineralocorticoid receptor antagonists for therapy of coronary artery disease and related complications. 2013 Apr 1
63 23349535 Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease? 2013 Feb 1
64 23456826 Rho kinase pathway is likely responsible for the profibrotic actions of aldosterone in renal epithelial cells via inducing epithelial-mesenchymal transition and extracellular matrix excretion. 2013 Jul 2
65 23582279 Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone. 2013 Dec 1
66 23661677 Mineralocorticoid receptor agonists induce mouse aortic aneurysm formation and rupture in the presence of high salt. 2013 Jul 1
67 23719402 Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study. 2013 Nov-Dec 1
68 23740451 Potential involvement of mineralocorticoid receptor activation in the pathogenesis of central serous chorioretinopathy: case report. 2013 May 1
69 23838006 Aldosterone signaling through transient receptor potential melastatin 7 cation channel (TRPM7) and its α-kinase domain. 2013 Nov 1
70 23881669 Eplerenone: a review of its use in patients with chronic systolic heart failure and mild symptoms. 2013 Sep 1
71 23888997 Mineralocorticoid receptor and cardiac arrhythmia. 2013 Dec 4
72 24120080 Cross-talk between mineralocorticoid receptor/angiotensin II type 1 receptor and mitogen-activated protein kinase pathways underlies aldosterone-induced atrial fibrotic responses in HL-1 cardiomyocytes. 2013 Oct 25 1
73 24133375 Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine. 2013 Oct 4 1
74 24231917 Management of patients with resistant hypertension: current treatment options. 2013 Oct 22 1
75 22205191 Mineralocorticoid receptor blocker eplerenone improves endothelial function and inhibits Rho-associated kinase activity in patients with hypertension. 2012 Feb 2
76 22214629 Eplerenone improved hypokalemia in a patient with Gitelman's syndrome. 2012 1
77 22411952 Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. 2012 May 1 1
78 22608985 Mitochondrial dysfunction accounts for aldosterone-induced epithelial-to-mesenchymal transition of renal proximal tubular epithelial cells. 2012 Jul 1 1
79 22684104 Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. 2012 Jul 1
80 22717248 Effects of aldosterone on human atherosclerosis: plasma aldosterone and progression of carotid plaque. 2012 Nov-Dec 1
81 22778046 Aldosterone receptor antagonists in cardiovascular disease: a review of the recent literature and insight into potential future indications. 2012 Oct 1
82 22791416 Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. 2012 Aug 2
83 23023156 Mineralocorticoid receptor blocker eplerenone reduces pain behaviors in vivo and decreases excitability in small-diameter sensory neurons from local inflamed dorsal root ganglia in vitro. 2012 Nov 2
84 21144811 [Aldosterone and kidney diseases: an emergent paradigm with important clinical implications]. 2011 Jun 1
85 21186336 Pathophysiological roles of aldosterone and mineralocorticoid receptor in the kidney. 2011 1
86 21190955 Aldosterone/Mineralocorticoid receptor stimulation induces cellular senescence in the kidney. 2011 Feb 2
87 21207206 Aldosterone-receptor antagonists in heart failure: insights after EMPHASIS-HF. 2011 Mar 1
88 21731887 Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure. 2011 1
89 21896143 Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics. 2011 Sep 1
90 22032706 Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. 2011 Nov 1 2
91 20535129 Aldosterone and mineralocorticoid receptor antagonists modulate elastin and collagen deposition in human skin. 2010 Oct 2
92 20625290 Aldosterone blockade in chronic kidney disease: can it improve outcome? 2010 Sep 1
93 18040710 Mineralocorticoid receptor is essential for corticosteroid-induced up-regulation of L-type calcium currents in cultured neonatal cardiomyocytes. 2008 May 1
94 18084345 Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist. 2008 Jan 2
95 18555797 Aldosterone modifies hemostasis via upregulation of the protein-C receptor in human vascular endothelium. 2008 Aug 22 1
96 18585409 Eplerenone inhibits the intracrine and extracellular actions of angiotensin II on the inward calcium current in the failing heart. On the presence of an intracrine renin angiotensin aldosterone system. 2008 Nov 29 2
97 18729003 Mineralocorticoid receptor antagonists and endothelial function. 2008 Sep 2
98 17596522 Aldosterone induces epithelial-mesenchymal transition via ROS of mitochondrial origin. 2007 Sep 2
99 17645055 [Aldosterone receptor antagonists]. 2007 May 30 1
100 17827916 [Molecular mechanism of cardiovascular damage induced by aldosterone]. 2007 Sep 1